Coronado Industries Moves Forward With PNT Treatment among the Caribbean Nations; Appoints Regional Adviser and Opens Negotiations with Governments and Private Agencies

Business Wire, March 10, 2005

FOUNTAIN HILLS, Ariz. -- Coronado Industries Inc. (OTC BB: CDIK), the manufacturer of the unique proprietary pneumatic devices for the non-invasive treatment of glaucoma, through its wholly owned subsidiary, Ophthalmic International, said today they have begun to explore the major Caribbean markets and have appointed Owen Bethel as regional consultant to the company.

In the past, discussions with the National Health System of Caribbean Island Nations around PNT were impeded due to Coronado Industries' lack of having a Health Authority registration within a major market such as the United States, Canada or key European countries. With the successful completion of the European Union 2A certification process and the active marketing of the company's proprietary PNT technology within the European community, interest has been rekindled with the Caribbean toward making PNT available to their medical community and national health systems. To that end, Coronado Industries is pleased to announce that it has appointed Bethel as regional consultant to the company.

Bethel is managing director of Montague Securities, Nassau, The Bahamas. He is a distinguished banker and financial adviser. His firm specializes in international finance and trade negotiations.

A leading member of The Bahamas' banking community, he was the founding director of The Bahamas Financial Services Secretariat and helped formulate many of the nation's international banking regulations.

Bethel will now assist Coronado's management on their current Caribbean-region marketing program.

In making the announcement, Richard Smith, Coronado's chairman and CEO, said he was delighted that the company was able to work with Bethel in reaching both governmental and private sector agencies in major markets throughout the Caribbean region.

Dr. John Sharkey, president of Ophthalmic International and Coronado's director of operations, has already had positive meetings in The Bahamas, and is scheduling additional meetings at this time with interested island governments.

Reviewing these developments, Dr. Sharkey said that the current exploration of market potential in the region was very much in line with Coronado's overall plan to expand the company's international marketing efforts and to secure revenue-producing distributive agreements in several markets throughout the world.

"We are very pleased to have Owen's advice and support in helping us gain access to a region that glaucoma has become an increasing concern," he said.

Coronado Industries' focus is on the development and commercialization of its patented PNT procedure as a cost-effective treatment of the most common types of glaucoma, which are open angle and pigmentary, as well as for the treatment of ocular hypertension.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.